BRASIL PHARMA S.A. - IN JUDICIAL REORGANIZATION

Publicly-Held Company

Corporate Taxpayer ID CNPJ/MF no. 11.395.624/0001-71

Company Registry (NIRE) 35.300.374.797

MATERIAL FACT

BRASIL PHARMA S.A. - IN JUDICIAL REORGANIZATION, a corporation registered in Brazilian Securities Commission ("CVM") as a category A publicly-held corporation, with headquarters in the City of São Paulo, State of São Paulo, at Avenida Presidente Juscelino Kubitschek, No. 1,830, Tower 4, 2nd and 3rd floors, Itaim Bibi, Zip Code 04543-900, with their certificate of incorporation registered at Junta Comercial do Estado de São Paulo under the Company Registry (NIRE) 35.300.374.797, enrolled with the Corporate Taxpayer ID CNPJ/MF under the no. 11.395.624/0001-71 ("Company"), in accordance with the article 157, paragraph 4th, of the Law No. 6,404/1976, as amended ("Corporate Law") and the CVM Instruction No. 358/2002, as amended, in continuity with the Material Facts previously disclosed by the Company in the ambit of its financial and corporate reorganization, hereby informs its shareholders and the market in general that the Company has decided to suspend the operational activities of fifty-three (53) units in the State of Bahia, one hundred (100) units in the State of Pará and sixty-four (64) units in the State of Pernambuco - components of drugstore chains Santana and Big Ben. The Company also informs that the operational activities of such units will remain suspended, in principle, until the conclusion and approval of the Company's Judicial Reorganization Plan, under the terms of the Law No. 11,101/2015.

The Company highlights that the suspension is aligned with the corporate strategies focused on expenditure reduction, analysis of fundraising alternatives, fine-tuning and new alternatives to rearrange its working capital, as well as resumption of investments, as disclosed in Material Fact disclosed by the Company on November 16, 2017. In addition, the Company emphasizes that the location agreements regarding such units remain in force.

The Company reiterates its commitment to keep shareholders and the market in general informed about the progress of the matters discussed here and of any other matter of market interest.

São Paulo, January 31, 2018.

Leonardo Leirinha Souza Campos

Investors Relations Officer

Brasil Pharma SA published this content on 01 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 01 February 2018 11:04:11 UTC.

Original documenthttp://ri.brasilpharma.com.br/Download.aspx?Arquivo=bBqMkT5iHuvpNfVPCjPSdg==

Public permalinkhttp://www.publicnow.com/view/F5D7E0AB7282D9A9E1A9F0611EA9FDEB0F46B85C